C.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial

Similar documents
Oral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine

Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy

P2Y 12 blockade. To load or not to load before the cath lab?

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Adults With Diagnosed Diabetes

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!

Stent Thrombosis Importance of Pharmacotherapy

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Novel Anticoagulation Therapy in Acute Coronary Syndrome

The use of percutaneous coronary intervention (PCI) as

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

Antiplatelet Therapy After PCI: How Much and How Long?

Optimal Duration and Dose of Antiplatelet Therapy after PCI

Adjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014

Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland

Columbia University Medical Center Cardiovascular Research Foundation

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Updated and Guideline Based Treatment of Patients with STEMI

Speaker s name: Thomas Cuisset, MD, PhD

Timing of Surgery After Percutaneous Coronary Intervention

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Antiplatelet Therapy: how, why, when? For Coronary Stenting

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Bivalirudin should be indicated for all patients with STEMI. Adnan Kastrati Deutsches Herzzentrum, Munich, Germany

Clopidogrel has been evaluated in clinical trials that included cardiovascular patients

Update on Antithrombotic Therapy in Acute Coronary Syndrome

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?

Clopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany

Antiplatelet Therapy. Briain Mac Neill

Antiplatelet therapy and Coronary Interventions. Georgios I. Papaioannou, MD Hartford Hospital Grand Rounds 4/22/2003

(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY

How Long Patietns Will Be on Dual Antiplatelet Therapy?

Perspective of LM stenting with Current registry and Randomized Clinical Data

Clinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition

Upstream P2Y 12 RB. Stefano Savonitto Divisione di Cardiologia Arcispedale S. Maria Nuova Reggio Emilia

Pathophysiology of ACS

Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary

Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI

Case Challenges in ACS The Very Elderly in the Cath Lab

Antiplatelet in diabetics: strong but incomplete umbrella

Prise en charge du SCA ST + en urgence. 9803mo01, 1

Clopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent

Δοκιμασίες λειτουργικότητας αιμοπεταλίων και PCI

Angioplastica coronarica nel paziente anziano ad alto rischio emorragico

ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium

Tim Henry, MD Director, Division of Cardiology Professor, Department of Medicine Cedars-Sinai Heart Institute

Update on the management of STEMI. Elliot Rapaport, M.D. San Francisco, CA December 14, 2007

Clinical Controversies in Perioperative Medicine

Clopidogrel and ASA after CABG for NSTEMI

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

Prevention of Coronary Stent Thrombosis and Restenosis

Is the role of bivalirudin established?

DECLARATION OF CONFLICT OF INTEREST

Dauer der doppelten Plättchenhemmung nach AMI / Stent

Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)

Antiplatelet therapy in ACS/PCI. Thomas Cuisset, CHU Timone, Marseille DIU Cardiologie Interventionnelle Paris, Janvier 2013

Management of cardiovascular disease - coronary interventions -

PPCI in STEMI. ESC at the 22nd Annual Conference of the Saudi Heart Association February 21th, 2011

Index. Note: Page numbers of article titles are in boldface type.

David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California

Patient characteristics Intervention Comparison Length of follow-up

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

An update on the management of UA / NSTEMI. Michael H. Crawford, MD

in High-risk PCI Patients?

Interventional Cardiology

Anti-platelet therapies and dual inhibition in practice

Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement

Stent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland

Disclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely

Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta

תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין

The Myth of Class Effect Antithrombotics Christopher Cannon, MD

Clopidogrel Date: 15 July 2008

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Additional Contributor: Glenn Levine (USA).

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

MINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı

PAR-1 Antagonist: What Do Clinical Trials Teach Us?

Measurement of Antiplatelet Therapeutic Efficacy

Adjunctive Pharmacological Therapies in PCI : Antiplatelets and Anticoagulants

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Issues in the Management of Diabetic Patients with Cardiovascular Disease

Acute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT

Otamixaban for non-st-segment elevation acute coronary syndrome

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

GENNARO SARDELLA MD, FACC,FESC

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.

Transcription:

Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20

Aim of the Study Safety and efficacy of a loading dose of Clopidogrel prior to elective PCI Safety and efficacy of 1 Year vs 1 Month combined treatment with Clopidogrel 75 mg + ASA after elective PCI

Inclusion Criteria Pts with symptomatic CAD scheduled for PCI without contraindications to antithrombotic or antiplatelet treatment or stent implantation and with no ST segment elevation within 24 hrs or planned staged procedures or recent (<7 days) administration of GP IIb-IIIa inhibitors, clopidogrel or thrombolytics

3-24 hrs before PCI 300 mg Clopidogrel Loading Dose + ASA 325 mg Placebo + ASA 325 mg GP IIb-IIIa Inhib. (mainly Abciximab) on prespecified or Bail-out Indications Clopidogrel 75 mg + ASA 325 mg for 1 Month 75 mg Clopidogrel + ASA 325 mg for 1 Year Placebo + ASA 325 mg for 1 Year 28 Days and 1 Year Clinical Follow-Up

Outcomes At 28 Days Death, MI, Urgent TVR in the per protocol population (all pts undergoing PCI) with prespecified secondary analysis of pts receiving clopidogrel loading dose or placebo <6 hrs or >6 hrs before PCI At 1 Year Death, MI, Stroke with prespecified secondary endpoints of TVR

Power Calculation based on a Retrospective Analysis of 2450 Pts in the EPISTENT trial: 28 Days Events 13.4% P<0.01 8.9% 7.5% No Ticlopidine Ticlopidine Expected Pre-PTCA Pre-PTCA for Clopid. Loading (expected placebo) Dose + 1 Year From Steinhubl et al, JACC 1998;32:1366-70

Clinical Characteristics (I) Clopidogrel Loading Dose + Clopidogrel 1 Year N= 1053 Placebo Loading Dose + Clopidogrel 1 Mo N= 1063 Age (yrs) 61+5 62+7 NS Male Sex (%) 70.7% 72.1% NS Diabetes (%) 27.5% 25.4% NS Statins (%) 53.6% 57.5% p=0.07 Ca ++ Chan. Block. (%) 25.5% 29.4% p=0.08 MI 14.3 13.1 Indication (%) UAP 52.5 53.1 NS SA 32.8 32.8 PTCA 85.6 86.2 Treatment (%) Medical 8.3 7.6 NS CABG 3.9 4.0

Clinical Characteristics (II) Clopidogrel Loading Dose + Clopidogrel 1 Year N= 900 Placebo Loading Dose + Clopidogrel 1 Mo N= 915 Received >1 Stent (%) 89.7 88.3 NS Total Stent Length (mm) 24.4 23.5 NS GP IIb-IIIa Antag. (%) 47.4% 43.3% p=0.08

Death, MI and Urgent TVR at 28 Days 10 8 6 4 2 0 NS -18.5% Clopid. No Loading Clopid. Loading 8.3% 6.8% 0 Days 7 14 21 28

Death, MI and Urgent TVR at 28 Days 10 8 6 4 2 0 P=0.051-38.6% Clopid. No Loading Clopid. < 6 Hrs Loading Clopid. > 6 Hrs 0 Days 7 14 21 28

Death, MI, Urgent TVR at 28 Days

15 10 5 0 Death, MI and Stroke at 1 Year P=.02 10.5% 8.5% -26% Clopid. 1 Mth Clopid. 1 Year 0 3 6 9 12 Mths

Death, MI, Stroke at 1 Year in Key Subgroups 0 1/2 4 24 48 Hrs

1 Year Primary and Secondary Prespecified EndPoints 1 Year Clopidogrel 1 Month Clopidogrel 13.1 13.6 6.7 8.4 1.7 2.3 0.9 0.9 Death MI Stroke TVR

Loading Dose-1 Year Clopidogrel Major Bleedings 1 Month Clopidogrel P = 0.24 8.8 P = 0.07 6.7 4.8 3.8 28 Days 1 Year More than ½ of major procedural bleedings due to CABG

Conclusions Prolongation of treatment with an ADP inhibitor such as clopidogrel beyond 1 month after PCIreduces the incidence of death/mi at 1 year There is a strong trend to reduction of death/mi/urgent TVR at 28 days after a loading dose of 300 mg of clopidogrel administered at least 6 hrs before PCI

Questions and Criticisms Did pretreatment interfere with long-term results? Did the poor compliance to long-term treatment with clopidogrel (only 63/61% of pts took the study drug) modify results? Can we improve it? Can we reduce the excess of bleeding?

Aspirin Dose and Bleeding Events in CURE 12563 Pts with non-st Elevation ACS Aspirin Alone (p=0.057) Aspirin/Clopidogrel (p=0.042) Major or Life Threatening Bleeding Events 4.63 4.64 1.92 2.82 2.24 3.19 3.32 3.77 ASA <100 mg 100-150 mg 150-300 mg >300 mg From Peters et al EHJ 2002;Suppl.4:510

Will a higher loading dose help? 10 + 10 Pts pretreated with 200 mg Aspirin 90 80 70 60 50 40 30 300 + 75 600 + 150 20 10 0 0 1/2 4 24 48 Hrs From Muller et al, Heart 2001;85:92-93

Do we still need IIb-IIIa inhibitors in pts with effective clopidogrel pretreatment? ISAR- REACT: after 600 mg loading dose Clopidogrel: Randomization to Abciximab or Placebo

TOPSTAR Study 109 Pts with 375 mg Clopidogrel and 500 mg ASA 24 Hrs before PCI Tirofiban 10 μg + 18 Hrs Infusion Placebo bolus + 18 Hrs infusion 100 100 128 108 87 98 10 14 Prior 30 min 12 Hrs 48 Hrs From Bonz et al, JACC 2002;40:662-8

TOPSTAR Study 109 Pts with 375 mg Clopidogrel and 500 mg ASA 24 Hrs before PCI Tirofiban 10 μg + 18 Hrs Infusion 40% Placebo bolus + 18 Hrs infusion 63% Positive Troponin T (>0.01 μg/ml) From Bonz et al, JACC 2002;40:662-8

Is 1 Year Treatment Enough? CHARISMA: 15000 Stable Angina Pts with 42 Mths F-Up From Metha et al, Lancet 2001;358:527-33 2658 Pts undergoing PCI in the CURE trial

Questions and Criticisms What about cost-effectiveness? Mechanism of clinical benefit? prevention of periprocedural damage, TVR late events and non TVR late events Long-term treatment with clopidogrel advised for pts who receive drug eluting stents (3 mths SIRIUS, 6 mths TAXUS)